INBX vs. SWTX, DNLI, TWST, ACLX, APGE, ADMA, CGON, NVAX, IOVA, and VCEL
Should you be buying Inhibrx stock or one of its competitors? The main competitors of Inhibrx include SpringWorks Therapeutics (SWTX), Denali Therapeutics (DNLI), Twist Bioscience (TWST), Arcellx (ACLX), Apogee Therapeutics (APGE), ADMA Biologics (ADMA), CG Oncology (CGON), Novavax (NVAX), Iovance Biotherapeutics (IOVA), and Vericel (VCEL). These companies are all part of the "biological products, except diagnostic" industry.
SpringWorks Therapeutics (NASDAQ:SWTX) and Inhibrx (NASDAQ:INBX) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, community ranking, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.
SpringWorks Therapeutics presently has a consensus target price of $68.83, indicating a potential upside of 71.36%. Inhibrx has a consensus target price of $27.00, indicating a potential upside of 57.34%. Given Inhibrx's stronger consensus rating and higher possible upside, research analysts plainly believe SpringWorks Therapeutics is more favorable than Inhibrx.
In the previous week, Inhibrx had 7 more articles in the media than SpringWorks Therapeutics. MarketBeat recorded 13 mentions for Inhibrx and 6 mentions for SpringWorks Therapeutics. Inhibrx's average media sentiment score of 1.33 beat SpringWorks Therapeutics' score of 1.05 indicating that SpringWorks Therapeutics is being referred to more favorably in the media.
82.5% of Inhibrx shares are held by institutional investors. 7.6% of SpringWorks Therapeutics shares are held by company insiders. Comparatively, 22.2% of Inhibrx shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Inhibrx has lower revenue, but higher earnings than SpringWorks Therapeutics. SpringWorks Therapeutics is trading at a lower price-to-earnings ratio than Inhibrx, indicating that it is currently the more affordable of the two stocks.
SpringWorks Therapeutics has a beta of 0.8, suggesting that its share price is 20% less volatile than the S&P 500. Comparatively, Inhibrx has a beta of 2.87, suggesting that its share price is 187% more volatile than the S&P 500.
SpringWorks Therapeutics received 60 more outperform votes than Inhibrx when rated by MarketBeat users. Likewise, 68.42% of users gave SpringWorks Therapeutics an outperform vote while only 60.78% of users gave Inhibrx an outperform vote.
SpringWorks Therapeutics has a net margin of 0.00% compared to SpringWorks Therapeutics' net margin of -13,408.95%. Inhibrx's return on equity of -66.48% beat SpringWorks Therapeutics' return on equity.
Summary
SpringWorks Therapeutics beats Inhibrx on 10 of the 18 factors compared between the two stocks.
Get Inhibrx News Delivered to You Automatically
Sign up to receive the latest news and ratings for INBX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding INBX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
